{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:32:24Z","timestamp":1790821944701,"version":"4.1.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"18","license":[{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T00:00:00Z","timestamp":1637625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s40265-021-01640-9","type":"journal-article","created":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T16:51:52Z","timestamp":1637686312000},"page":"2159-2166","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Penpulimab: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sohita","family":"Dhillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,23]]},"reference":[{"issue":"1","key":"1640_CR1","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-018-0578-4","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. J Hematol Oncol. 2018;11(1):31.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"1640_CR2","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48(3):434\u201352.","journal-title":"Immunity"},{"issue":"12","key":"1640_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin P, Toor SM, Sasidharan Nair V, et al. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018;50(12):1\u201311.","journal-title":"Exp Mol Med"},{"issue":"2","key":"1640_CR4","doi-asserted-by":"publisher","first-page":"e001754","DOI":"10.1136\/jitc-2020-001754","volume":"8","author":"A Naing","year":"2020","unstructured":"Naing A, Hajjar J, Gulley JL, et al. Strategies for improving the management of immune-related adverse events. J Immunother Cancer. 2020;8(2):e001754.\u00a0https:\/\/doi.org\/10.1136\/jitc-2020-001754.","journal-title":"J Immunother Cancer"},{"issue":"15 Suppl","key":"1640_CR5","doi-asserted-by":"publisher","first-page":"7529","DOI":"10.1200\/JCO.2021.39.15_suppl.7529","volume":"39","author":"Y Song","year":"2021","unstructured":"Song Y, Zhou K, Jin C, et al. A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractoryclassic Hodgkin lymphoma (cHL) [abstract no. 7529]. J Clin Oncol. 2021;39(15 Suppl):7529.","journal-title":"J Clin Oncol"},{"issue":"15 Suppl","key":"1640_CR6","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1200\/JCO.2021.39.15_suppl.8568","volume":"39","author":"C Zhang","year":"2021","unstructured":"Zhang C, Yang S, Chen J, et al. Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy [abstract no. 8568]. J Clin Oncol. 2021;39(15 Suppl):8568.","journal-title":"J Clin Oncol"},{"key":"1640_CR7","unstructured":"Akeso Inc. Penpulimab monoclonal antibody (PD-1) obtains marketing approval in China [media release]\u00a0 5 Aug 2021. https:\/\/www.akesobio.com."},{"key":"1640_CR8","unstructured":"Akeso Inc. Penpulimab \u5b89\u5c3c\u53ef\u00ae: Chinese prescribing information. Zhongshan City, 2021."},{"key":"1640_CR9","unstructured":"Akesobio. Akesobio 2020 Annual Report. 2021. https:\/\/www.akesobio.com\/media\/1411\/2021042900543.pdf. Accessed 6 Sept 2021."},{"key":"1640_CR10","unstructured":"Akesobio. Foreign cooperation. 2021. https:\/\/www.akesobio.com\/en\/collaborations\/. Accessed 6 Sept 2021."},{"issue":"Suppl 3","key":"1640_CR11","doi-asserted-by":"publisher","first-page":"A481","DOI":"10.1136\/jitc-2020-SITC2020.0454","volume":"8","author":"X Chen","year":"2020","unstructured":"Chen X, Wang W, Zou Q, et al. A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy [abstract no. 804]. J Immunother Cancer. 2020;8(Suppl 3):A481.","journal-title":"J Immunother Cancer"},{"issue":"15 Suppl","key":"1640_CR12","doi-asserted-by":"publisher","first-page":"e21072","DOI":"10.1200\/JCO.2021.39.15_suppl.e21072","volume":"39","author":"B Han","year":"2021","unstructured":"Han B, Chen J, Wang Z, et al. Penpulimab in combination with anlotinib as first-line treatment in advanced nonsquamous nonsmall-cell lung cancer [abstract no. e21072]. J Clin Oncol. 2021;39(15 Suppl):e21072.","journal-title":"J Clin Oncol"},{"issue":"3 Suppl","key":"1640_CR13","doi-asserted-by":"publisher","first-page":"S650","DOI":"10.1016\/j.jtho.2021.01.1189","volume":"16","author":"B Han","year":"2021","unstructured":"Han B, Chen J, Xie Q, et al. A multicenter, randomized, phase 3 trial of penpulimab in combination with anlotinib or chemotherapy as first-line treatment in advanced NSCLC [abstract no. P80.01]. J Thorac Oncol. 2021;16(3 Suppl):S650.","journal-title":"J Thorac Oncol"},{"key":"1640_CR14","doi-asserted-by":"publisher","first-page":"684867","DOI":"10.3389\/fonc.2021.684867","volume":"11","author":"C Han","year":"2021","unstructured":"Han C, Ye S, Hu C, et al. Clinical activity and safety of penpulimab (anti-PD-1) with anlotinib as first-line therapy for unresectable hepatocellular carcinoma: an open-label, multicenter, phase Ib\/II trial (AK105-203). Front Oncol. 2021;11:684867.","journal-title":"Front Oncol"},{"issue":"Suppl 15","key":"1640_CR15","doi-asserted-by":"publisher","first-page":"e14006","DOI":"10.1200\/JCO.2019.37.15_suppl.e14006","volume":"37","author":"D Kotasek","year":"2019","unstructured":"Kotasek D, Coward J, De Souza PL, et al. A phase I dose escalation and dose expansion study of the anti-programmed cell death-1 (PD-1) antibody AK105 [abstract no. e14006]. J Clin Oncol. 2019;37(Suppl 15):e14006.","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"1640_CR16","first-page":"S1300-S1","volume":"31","author":"ARA Mislang","year":"2020","unstructured":"Mislang ARA, Coward J, Cooper A, et al. Efficacy and safety of penpulimab (AK105), a new generation anti-programmed cell death-1 (PD-1) antibody, in upper gastrointestinal cancers [abstract no. 157P]. Ann Oncol. 2020;31(Suppl 6):S1300\u20131.","journal-title":"Ann Oncol"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01640-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01640-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01640-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T16:16:47Z","timestamp":1638807407000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01640-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,23]]},"references-count":16,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1640"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01640-9","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,23]]},"assertion":[{"value":"23 November 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sohita Dhillon is a contracted employee of Adis International Ltd\/Springer Nature and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval,\u00a0Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}